Influence of Natural Lung Surfactant Inhalations on Clinical Symptoms and Pulmonary Function Parameters in Patients with Bronchial Asthma. Communication 1

Степанова, О. В.; Akulova, E.; Kochneva, Aleksandra; Seiliev, A. A.; Shulga, A.; Lovacheva, Olga; Lukyanov, S. A.; Шаповалов, К. Г.; Volchkov, Vladimir; Rosenberg, O.

doi:10.21103/article6(4)_oa1

Cited by 4 publications

(2 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(7) Follow-up according to the Protocol allowed us to evaluate the dynamics of BA clinical manifestations after 21 inhalations (Day 70) and at the following 9 visits, in comparison with the baseline. The results of the evaluation are presented in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…The 41-day surfactant therapy course consisting of 16 inhalations has allowed ICS dose reduction by 2 times. (7) The objective of this study was to evaluate the effectiveness of surfactant treatment based on the evaluation of clinical manifestations in BA patients who have received a course of surfactant therapy comprising 21 inhalations of Surfactant-BL (Biosurf, Russia) over 70 days and who have been followed up for 340 days.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Natural Lung Surfactant Inhalations on Clinical Symptoms and Pulmonary Function Parameters in Patients with Bronchial Asthma. Communication 2

Akulova¹,

Степанова²,

Seiliev³

et al. 2017

IJBM

Self Cite

View full text Add to dashboard Cite

Background: Damage to lung surfactant (LS) enabling the lung local immunity may contribute to the development of bronchial inflammation in patients with bronchial asthma (BA). Methods and Results:A 70-day course of 21 LS (Surfactant-BL) inhalations at the dose of 25 mg was added to inhaled corticosteroids (ICS) and short/long-acting bronchodilators or combined inhalers in 13 BA patients. After 21 inhalations, many patients reported lower frequency of cough and profuse expectoration, fewer night and day attacks, resolution of wheezing, resolution or lower frequency of bronchospasm episodes under moderate exercise, and termination (1 patient) or double reduction Conclusion: LS inhalations improve the condition of patients with BA, allow ICS dose reduction by 2 times, and improve pulmonary function parameters. A total of 70% of patients had quite a long remission of BA symptoms following a 21-inhalation therapy course of the formulation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%